News | February 05, 2026
AstraZeneca & Daiichi Sankyo gain priority review for Datroway in hard-to-treat breast cancer
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
The FDA’s regulatory decision is expected in Q2 2026 under the Prescription Drug User Fee Act (PDUFA)
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
